Vergelijking
Mazdutide vs. Pemvidutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
2259884-03-0
geen gegevens
Molecuulmassa
4790 g/mol
geen gegevens
Halfwaardetijd
132 h
geen gegevens
Sequentie
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkettegeen gegevens
Werkingsmechanisme
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Pemvidutide
The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane studie
Studies
4
1
waarvan bij mensen
4
1
Geregistreerde effecten
4
2
Openstaande tegenstrijdigheden
0
0
Gedocumenteerde bijwerkingen
0
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Mazdutide and Pemvidutide?
- Mazdutide is classified as "Metabool", while Pemvidutide is classified as "Metabool". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Pemvidutide?
- The highest available evidence level is "Humane RCT" for Mazdutide and "Humane studie" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Pemvidutide in Germany and the United States?
- Duitsland: Mazdutide — Alleen onderzoek, Pemvidutide — Niet goedgekeurd. Verenigde Staten: Mazdutide — Alleen onderzoek, Pemvidutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.